178 related articles for article (PubMed ID: 32565118)
1. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
[TBL] [Abstract][Full Text] [Related]
2. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
Checchi M; Mesher D; Mohammed H; Soldan K
Sex Transm Infect; 2019 Aug; 95(5):368-373. PubMed ID: 30723186
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
4. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.
Naleway AL; Crane B; Smith N; Francisco M; Weinmann S; Markowitz LE
Sex Transm Dis; 2020 Mar; 47(3):179-186. PubMed ID: 31880738
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
6. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815
[TBL] [Abstract][Full Text] [Related]
7. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.
Flagg EW; Torrone EA
Am J Public Health; 2018 Jan; 108(1):112-119. PubMed ID: 29161070
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
9. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
[TBL] [Abstract][Full Text] [Related]
11. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
Tyros G; Mastraftsi S; Gregoriou S; Nicolaidou E
Int J STD AIDS; 2021 Jan; 32(1):4-13. PubMed ID: 33167803
[TBL] [Abstract][Full Text] [Related]
12. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
Sandø N; Kofoed K; Zachariae C; Fouchard J
Acta Derm Venereol; 2014 May; 94(3):288-92. PubMed ID: 24150529
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
14. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
[TBL] [Abstract][Full Text] [Related]
17. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
Righolt CH; Willows K; Kliewer EV; Mahmud SM
PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
[TBL] [Abstract][Full Text] [Related]
18. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study.
Baandrup L; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2021 Nov; 73(9):e3220-e3226. PubMed ID: 33048118
[TBL] [Abstract][Full Text] [Related]
19. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
20. Impacts of Human Papillomavirus Immunization Programs on Rates of Anogenital Warts in British Columbia, Canada, 2000 to 2017.
Lukac CD; Donken R; Otterstatter M; Mazo O; Wong S; Marra F; Smith L; Naus M; Money D; Krajden M; Grennan T; Gilbert M; Wong J; Ogilvie GS
Sex Transm Dis; 2020 Oct; 47(10):691-697. PubMed ID: 32649583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
